Medical Device

Medtronic plc the global leader in medical technology, and Surgical Theater today announced a partnership to interface Surgical Theater's Sync AR ™ augmented reality technology with Medtronic's StealthStation™ S8 surgical navigation system. This collaboration will enable neurosurgeons to use AR technology in real-time to enhance visualization during complex cranial procedures. Using fighter-jet simulation ...

- Medtronic plc (NYSE:MDT), the global leader in medical technology, and Surgical Theater today announced a partnership to interface Surgical Theater's Sync AR ™ augmented reality (AR) technology with Medtronic's StealthStation™ S8 surgical navigation system. This collaboration will enable neurosurgeons to use AR technology in real-time to enhance visualization during complex cranial procedures. Using fighter-jet simulation technology, the Sync AR platform allows surgeons to visualize structures in the brain, test virtual surgical tools and plan surgeries before entering the operating room. By integrating this technology with the StealthStation S8 cranial solution, surgeons can expand the benefits of AR and, for the first time, see a 360° AR rendering overlaid onto the live surgical site during brain surgeries.

"Sync AR offers important benefits in planning and practicing how to approach complex cases, and now being able to actually use AR during procedures to see where instruments are in relation to critical structures while never losing focus on the patient is a significant advance," said Thomas Steineke , M.D., chairman, JFK Neurosciences Institute, Edison, N.J. "In neurosurgery, it's paramount to correctly identify and navigate critical brain structures. AR-enhanced visualization interfacing with the StealthStation will help me achieve the best possible outcomes for my patients."

Treatment of brain tumors, aneurysms and neurological conditions are among the riskiest and most complex surgical procedures. Real-time access to the most detailed patient-specific information, such as the space between vascular structures, arteries and white matter location, is critical.

Surgical Theater's Sync AR technology synchronizes with Medtronic's StealthStation S8 navigation system and microscope optics to provide unparalleled tools that may help surgeons accomplish complicated procedures with increased precision and efficiency. The combination of the StealthStation S8 and Sync AR technology is designed to give surgeons the ability to see otherwise hidden anatomical and vascular structures, pathologies, and Diffusion Tensor Imaging (DTI) white matter tracts synchronized and aligned to the surgeon's operative view. A 360° AR rendering, created from the patient's scans, is overlaid onto the live image viewed through the oculars of the microscope as they track the positioning of their surgical tools, allowing surgeons to keep their eyes focused on the patient.

"Medtronic's partnership with Surgical Theater expands the utility of cutting-edge AR planning technology, so that surgeons can use it in real-time to improve visualization during brain surgeries, which has the potential to make procedures more precise and efficient," said Linnea Burman , vice president and general manager, Enabling Technologies within the Cranial & Spinal Technologies business, which is part of the Neuroscience Portfolio at Medtronic. "We are thrilled to partner with Surgical Theater as we strive to transform cranial procedures and improve outcomes by providing surgeons with access to innovative technologies."

The StealthStation S8 navigation system combines hardware and clinical software with tracking and image dataset merging algorithms, to precisely track surgical instruments and help guide the user during surgical procedures. Surgical Theater's Sync AR 360° Visualization Hub offers surgeons live and synchronized augmentation including vascular structures, pathology, and white matter tracts aligned to their surgical field of view.

Surgical Theater, the market leader in virtual and augmented reality healthcare services, is the first to combine cutting-edge fighter jet flight simulation technology with a patient's own anatomy scans. Rendered from comprehensive combined modalities of CT, MRI, as well as advanced post processing images, the 360° virtual reality fly-through is designed to allow surgeons to walk and fly-through a reconstruction of the patient's own anatomy and pathology.

"We believe by combining Medtronic's market-leading surgical navigation, and Surgical Theater's trailblazing visualization capabilities, Sync AR technology now offers the most comprehensive solution for neurosurgical planning, workflow and operative execution," said Moty Avisar , CEO and co-founder of Surgical Theater. "Sync AR technology does not stop at planning and navigation; we open the skull, provide surgeons with x-ray vision of the anatomy and play an integral role throughout the operative workflow."

About Surgical Theater
Surgical Theater, the leader in 360° XR visualization, powers patients and their surgeons with clinical insights by providing them an immersive, inside out view of their patient's anatomy, enabling them to see the unseen. This is the only end-to-end solution with peer reviewed data that is utilized throughout the patient's surgical care continuum –from patient engagement, surgical planning, physician interdisciplinary collaboration and into the OR.  Supporting more than 15,000 surgeries and utilized in over 100,000 patient consultations, 360° XR vertically integrates the institution, medical provider and patient, under a shared goal of improved outcomes.

About Medtronic
Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland , is among the world's largest medical technology, services, and solutions companies – alleviating pain, restoring health, and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals, and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:



Kyra Nead

Ryan Weispfenning

Public Relations

Investor Relations

+1-303-886-2549

+1-763-505-4626

Medtronic plc (PRNewsfoto/Medtronic plc)

Cision View original content to download multimedia: http://www.prnewswire.com/news-releases/medtronic-partners-with-surgical-theater-to-provide-first-augmented-reality-platform-for-use-in-real-time-during-complex-cranial-procedures-301276465.html

SOURCE Medtronic plc

News Provided by PR Newswire via QuoteMedia

Applied UV Announces Order for The Renaissance Cleveland Hotel

Applied UV Announces Order for The Renaissance Cleveland Hotel

$2M Furnishings Order Expected Subject to Initial "Model Room" Product Approval

Applied UV, Inc. (NasdaqCM: AUVI ) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announces that its wholly owned subsidiary MunnWorks, a custom manufacturer of luxury mirrors and furniture for the hospitality market, has received a model room order from The Renaissance Cleveland Hotel , which will be fully funded by the developer of the hotel. Upon successful acceptance of the "Model Room" order, a follow-on $2M order is expected. This order for hotel furniture will be manufactured in MunnWorks 100,000 square foot Brooklyn, NY manufacturing facility, which MunnWorks acquired on March 31 st , 2022, through the purchase of VisionMark LLC's luxury furniture manufacturing business.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Medtronic receives FDA approval for latest generation drug-eluting coronary stent system

The Onyx Frontier™ drug-eluting stent offers an innovative delivery system and builds upon the acute performance and clinical data from the Resolute Onyx™ drug-eluting stent

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received U.S. Food and Drug Administration (FDA) approval for the Onyx Frontier™ drug-eluting stent (DES). As the latest evolution in the Resolute DES family, Onyx Frontier DES leverages the same best-in-class stent platform as Resolute Onyx™ DES, with an enhanced delivery system 1 designed to improve deliverability and increase acute performance 2 in even the most challenging of cases. 1

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Danaher Joins Bespoke Gene Therapy Consortium for Rare Diseases

Consortium aims to speed the development and delivery of customized or 'bespoke' gene therapies

Danaher Corporation (NYSE: DHR) announced that it has joined the Bespoke Gene Therapy Consortium (BGTC). Launched in October 2021 the BGTC will generate gene therapy resources that the research community can use to streamline gene therapy development for rare disorders, making the process more efficient and less costly. Danaher's Life Science companies join the Food and Drug Administration (FDA), the National Institutes of Health (NIH), twelve pharmaceutical and biotech companies and nine non-profits, and will be represented by experts from Danaher Corporation and its companies, notably Pall Corporation, Aldevron and Cytiva. The project is managed by the Foundation for the National Institutes of Health (FNIH) as part of the Accelerating Medicines Partnership® program.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Johnson & Johnson to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 43 rd Annual Global Healthcare Conference at the Terranea Resort, Rancho Palos Verdes, CA on Thursday, June 16 th . Jennifer Taubert Executive Vice President, Worldwide Chairman, Pharmaceuticals will represent the Company in a session scheduled at 1:00 p.m. (Eastern Time) .

This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Johnson & Johnson to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 43 rd Annual Global Healthcare Conference at the Terranea Resort, Rancho Palos Verdes, CA on Thursday, June 16 th . Jennifer Taubert Executive Vice President, Worldwide Chairman, Pharmaceuticals will represent the Company in a session scheduled at 1:00 p.m. (Eastern Time) .

This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Knight Therapeutics Reports First Quarter 2022 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company"), a leading Pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2022. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.

Q1 2022 Highlights

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×